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RESUME 
Le traitement médical de la rhinosinusite chronique (RSC) pose un problème de santé 
publique en raison, entre autres, de la fréquence des récidives infectieuses nécessitant une 
antibiothérapie  et du prix des corticostéroïdes topiques. L’ hypochlorite de sodium (NaOCl) 
est un agent bactéricide efficace contre toutes les souches bactériennes potentiellement 
pathogènes. Le but de cette étude a été de déterminer la cytotoxicité du NaOCl  sur des 
cellules épithéliales respiratoires primaires cultivées in vitro. Nous avons déterminé la 
concentration (0.05 %) et la durée (5 min 2 x par jour) d’exposition au NaOCl n’ayant pas 
d’effet cytotoxique tout en conservant ses propriétés bactéricides. Nous avons évalué, chez 
des patients symptomatiques, l’effet thérapeutique de lavages des fosses nasales avec une 
solution de NaOCl à 0.05 %  2 fois par jour pendant 3 mois. L’intensité subjective des 
symptômes et les paramètres cliniques endoscopiques ont été évalués par des échelles 
analogiques visuelles. Nous avons mesuré la résistance respiratoire nasale par 
rhinomanométrie et la production nasale de monoxyde d’azote (NO) avant et après le 
traitement.  
Le lavage des fosses nasales 2 fois par jour avec une solution de NaOCl 0.05 % semble 
améliorer de façon significative la plupart des symptômes et des paramètres inflammatoires 
endoscopiques de la RSC.  
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INTRODUCTION 
Rhino-sinusite chronique : 
La rhino-sinusite chronique (RSC) est un des problèmes les plus fréquents de santé au niveau 
mondial avec des conséquences socio-économiques majeures. L’étiologie de la RSC est 
probablement multifactorielle. Le rôle et le type des bactéries qui pourraient être impliquées 
dans la physiopathologie de cette maladie sont l’objet de nombreux travaux de recherche. A 
l’heure actuelle, le traitement médical classique de la RSC inclut très souvent une 
antibiothérapie. Bien que le choix de l’antibiotique devrait toujours être accompagné d’un 
examen bactériologique et d’un antibiogramme, dans la plupart des cas le type d’antibiotique 
est choisi de façon empirique (1, 2). Un nombre croissant d’antibiotiques ont progressivement 
perdu de leur efficacité contre les bactéries les plus fréquemment rencontrées dans la RSC. 
L’émergence de souches bactériennes multirésistantes aux antibiotiques est probablement 
d’origine multiple et inclut probablement l’usage abusif de ce type de médicaments 
antimicrobiens. L’introduction de nouveaux antibiotiques a diminué au cours des dernières 
années et les nouveaux agents développés ont malheureusement été associés au 
développement rapide de nouvelles souches résistantes (2, 5). C’est ainsi que de nouvelles 
alternatives thérapeutiques concernant le traitement des rhino-sinusites chroniques associées à 
la présence de bactéries sont devenues un sujet en plein développement.  
Le traitement classique de la RSC comprend des lavages des fosses nasales, l’application de 
corticoïdes topiques, la prise prolongée d’antibiotiques à large spectre et parfois des 
antihistaminiques (3, 4). En cas d’échec du traitement traditionnel médical et en présence 
d’anomalies anatomiques révélées par le scanner du massif facial, on peut proposer une 
chirurgie endoscopique rhino-sinusienne (5). Selon la littérature disponible, la chirurgie 
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endoscopique rhino-sinusienne est un geste dont les résultats à long terme sont plutôt 
satisfaisants (1). Cependant, il existe un pourcentage significatif de patients qui n’ont pas été 
améliorés par le traitement chirurgical. Dans les cas de surinfection chronique, on peut 
proposer une antibiothérapie intraveineuse pendant plus de 6 semaines (8), des lavages 
sélectifs des sinus avec des solutions antibiotiques ou des corticostéroïdes (6,9).  
La rhino-sinusite chronique a un impact financier important. Quatre vingt cinq % des patients 
souffrant de RSC sont en âge de travailler (entre 18 et 65 ans) et les coûts indirects 
secondaires dus par exemple à l’absentéisme ou au présentéisme, c’est à dire une baisse de la 
productivité lors de l’activité professionnelle, semblent affecter de façon importante l’aspect 
économique de cette maladie (1). Les coûts directs incluent le bilan radiologique, 
l’hospitalisation et le traitement médicamenteux. Aux Etats-Unis, les dépenses annuelles en 
médicaments pour le traitement de la RSC avant et après chirurgie ont été évalués à 1.220 $ et 
629 $ par patient et par an, respectivement (10). Le traitement chirurgical coûte en moyenne 
6.490 $ par patient.  A la vue de ces chiffres importants, une alternative à ces prises en charge 
thérapeutiques pourrait se révéler intéressante. 
L’hypochloride de soude : 
L’hypochloride de soude (NaOCl) est un agent chimique bien connu utilisé essentiellement 
pour ses propriétés de décoloration et blanchiment du linge ainsi que son action désinfectante 
(11-19). Ces propriétés bactéricides ont été observées contre de multiples organismes, en 
particulier le staphylocoque doré (11-16), le pseudomonas aeruginosa (18), le candida 
albicans (18) et le vibrio vunificus (19). En fait, le NaOCl semble être efficace contre toutes 
les bactéries connues pour infecter les plaies des patients brûlés (14). L’hypochloride de 
soude a été utilisé pour le lavage des plaies par Bugnan pendant la 2ème guerre mondiale. Sur 
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les brûlures, les lavages étaient effectués avec une solution d’hypochloride de soude à 0,2%. 
Elles étaient ensuite recouvertes par un pansement à base de soie contenant du NaOCl à 
0,05%. L’effet antiseptique du NaOCl a déjà été observé par Koch en 1880 et Dakin l’a utilisé 
pour le traitement des plaies pendant la 1ère guerre mondiale (14, 18, 20). De nos jours, le 
NaOCl est l’agent le plus utilisé pour les traitements antiseptiques stomatologiques et 
parodontiques (11, 17, 20-22).  
Le mécanisme exact des propriétés bactéricides du NaOCl n’a jamais été déterminé. En 
présence d’eau, le NaOCl se dissocie en Na+ et OCl-/HOCl (acide hypochlorique). La 
chlorine active est un puissant agent oxydant. Des observations expérimentales semblent 
suggérer que la chlorine exerce son effet antimicrobien par une oxydation irréversible des 
groupes SH présents dans certaines enzymes et en induisant un blocage des fonctions 
métaboliques essentielles des cellules bactériennes. La chlorine peut également se combiner 
avec des composants cytoplasmiques pour former des complexes N-chloro qui sont également 
toxiques pour les micro-organismes (14, 20, 22).  
Le choix d’une concentration appropriée de NaOCl dépend d’un bon équilibre entre les 
propriétés antibactériennes et des éventuelles toxicités tissulaires. Traditionnellement, le choix 
de la concentration varie entre 0,5% jusqu’à 5,25% avec parfois des concentrations pouvant 
aller jusqu’à 10% (17). Cependant, les effets bactéricides du NaOCl ont déjà été observés à 
des concentrations aussi basses que 0,025% lorsqu’il est utilisé sur des pansements occlusifs 
(23). Dans le cas des irrigations des lésions parodontiques ou stomatologiques, les propriétés 
antimicrobiennes d’une solution à 0,5% de NaOCl semblent être significativement moins 
efficaces que les concentrations à 5,25% (22). En augmentant le temps d’exposition à une 
solution de NaOCl on diminue également la survie des micro-organismes. Si le temps 
d’exposition est augmenté, une solution à 0,5% de NaOCl semble avoir le même effet 
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bactéricide qu’une solution à 5,25% (21). Dans les traitements à long terme, il semble qu’une 
solution à 0,5% ne soit pas appropriée. En effet, après 2 semaines de traitement continu sur 
des brûlures recouvertes avec de la gaze imbibé de NaOCl, une toxicité marquée a été 
observée au niveau des cellules de l’épiderme. Les cellules basales de l’épiderme qui ont été 
isolées dans les régions traitées semblaient avoir une croissance fortement perturbée. 
Cependant, une solution à 0,1% de NaOCl semble avoir une faible toxicité pour les 
traitements à long terme. 
Avant d’utiliser une solution de NaOCl chez nos patients souffrant de RSC, nous avons 
d’abord évalué la toxicité de différentes concentrations de NaOCl et de temps d’exposition sur 
des cultures primaires de cellules épithéliales respiratoires cultivées in vitro.  
Effets d’une solution de NaOCl sur la F-actine et les jonctions serrées intercellulaires : 
La F-actine est un constituant du cytosquelette qui est impliquée dans la stabilisation de la 
forme des cellules et joue également un rôle important dans la distribution des protéines 
membranaires. D’autre part, la F-actine est également impliquée dans les transports 
transmembranaires et dans la régulation du volume cellulaire (24, 25). La F-actine est 
également directement liée à de nombreux composants des jonctions serrées intercellulaires. Il 
semblerait donc qu’une altération de l’expression de la F-actine pourrait avoir des effets 
importants sur la structure des jonctions serrées intercellulaires (26). 
Ezrine : 
La polarisation des cellules epithéliales en culture dépend de l’adhésion intercellulaire, de 
l’organisation du cytosquelette et de la répartition de certaines protéines dans les 
compartiments baso-latéraux et apicaux. Les protéines spécialisées du pôle apical des 
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membranes cellulaires dépendent essentiellement de certaines protéines polarisées comme 
l’ezrine, la radixine et la moesine (ERM) qui sont issues d’un lage pool cytoplasmique. En 
mettant en évidence l’expression de l’ezrine, on peut suivre assez facilement la différentiation 
et la polarisation des cellules épithéliales respiratoires cultivées in vitro (27).  
Résistance électrique transépithéliale : 
Les jonction serrées, qui sont classiquement localisées sur les bordures apico-latérales des 
cellules épithéliales, régularisent de façon sélective le passage de l’eau, des ions et de 
certaines molécules neutres ainsi que des cellules inflammatoires à travers les voies de 
passage paracellulaires. Ces jonctions serrées définissent les limites de certains compartiments 
liquidiens, qui sont vitaux pour l’homéostase cellulaire et qui contribuent également au 
maintien de la polarité cellulaire. Une des façons les plus efficaces d’évaluer le bon 
fonctionnement de ces jonctions serrées est de mesurer sur des cultures primaires de cellules 
épithéliales in vitro la présence d’une résistance électrique transépithéliale. La résistance 
électrique transépithéliale générée à travers un épithélium est déterminée par les transports 
ioniques et l’effet sélectif et restrictif des jonctions serrées (28). 
Evaluation clinique : 
La RSC et la polypose nasale peuvent être définies comme une inflammation des muqueuses 
nasales et des sinus paranasaux caractérisée par 2 ou 3 des symptômes suivant pendant plus de 
3 mois : obstruction ou congestion des voies aériennes nasales ; écoulement antérieur et/ou 
postérieur ; douleurs ou pression faciales ; diminution ou perte des performances olfactives. 
Les signes endoscopiques associés au diagnostic clinique de RSC sont la présence de polypes 
au méat moyen, un écoulement mucopurulent au niveau du méat moyen ou un œdème 
muqueux obstruant partiellement le complexe ostioméatal du méat moyen. Les signes 
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radiologiques sont : un épaississement mucopériosté diffus essentiellement localisé au niveau 
du méat moyen ou des sinus paranasaux (1). 
L’évaluation subjective de l’intensité des symptômes associés à la RSC peut être mesurée en 
utilisant une échelle analogique visuelle (EAV). Concernant l’obstruction par exemple, 
l’absence de ce symptôme correspondrait à la valeur 0 sur l’EAV et une obstruction complète 
pourrait correspondre à la valeur de 10. Les EAV permettent une quantification reproductible 
des symptômes spécifiques de la RSC (7). 
Monoxyde d’azote : 
La production de monoxyde d’azote (NO) par les voies respiratoires semble être un indicateur 
assez spécifique de la présence de cellules inflammatoires et d’un dysfonctionnement du 
transport mucociliaire. La mesure de la production de NO par les voies respiratoires 
supérieures a souvent été utilisée comme paramètre permettant d’évaluer l’évolution de la 
maladie après un traitement chirurgical (1). La production de NO au niveau des fosses nasales 
est une des plus hautes de l’ensemble du corps humain (29). La production de NO est en 
général mesurée par la technique de chémiluminescence (30).  
Rhinomanométrie : 
La rhinomanométrie permet de mesurer de façon objective la résistance respiratoire nasale. 
Cette mesure objective permet également une bonne évaluation du traitement chirurgical et/ou 
médical de la rhino-sinusite chronique (31). 
But de l’étude : 
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L’objectif principal de cette étude a été d’évaluer l’efficacité des lavages des fosses nasales 
avec une solution d’NaOCl chez les patients souffrant de RSC associée à des infections loco-
régionales récidivantes. 
Les effets cytotoxiques potentiels de différentes concentrations de NaOCl ou de temps 
d’exposition ont été évalués sur des cultures primaires de cellules épithéliales respiratoires in 
vitro. 
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SUMMARY 
Treatment of chronic rhinosinusitis (CRS) is arduous as a result of increasing resistance to 
antibiotics and expenses of topical corticosteroids among other factors. Finding an alternative 
therapy is important. Sodium hypochlorite (NaOCl) is an established disinfecting agent with 
no known bacterial resistance. No literature has been found on NaOCl use for CRS and its 
effect in all tissues may not be the same. Selection of NaOCl is based on anti-microbial 
affectivity and cytotoxicity. The aim of this study was to determine the appropriate 
concentration and application method of NaOCl and evaluate its clinical efficiency in CRS. 
Two concentrations of NaOCl were prepared by diluting 0.55% NaOCl (Amuchina Med) with 
normal saline (0.9% NaCl). In vitro tests for cilia and epithelial cell viability were done on 
reconstituted epithelial cells by primary epithelial cells cultured in vitro. Cells were exposed 
for 5 and 15 minutes twice daily for 5 consecutive days to one of the following conditions, 1) 
untreated and 2) 0.5% NaOCl and 0.05% NaOCl. Transepithelial resistance (TER) was 
measured. In order to visualize cell integrity and test for cilia, immunostaining was done for 
ezrin and F-actin network and observed with confocal microscopy. After the determination of 
optimal NaOCl concentration in vitro, in vivo tests were performed. Patients with CRS 
without any known risk factor for increased infection were selected. Each patient applied 
NaOCl as nasal lavage twice daily on both nostrils for 3 months. Symptom intensity and 
endoscopic findings were recorded with visual analogue scale (VAS) and nasal airway 
resistance (NAR) and nasal Nitric Oxide (NO) level were measured at baseline and after 3 
months. Fourteen patients completed the study. F-actin network loss and decreased expression 
of ezrin was significant in cells exposed to 0.5% than 0.05% NaOCl and more obvious when 
exposed for longer periods (15 min. and 5 min.) daily. Statistically significant improvement in 
nasal obstruction (p=0.001), posterior nasal discharge (p=0.018), smell (p=0.007) and 
 10
headache (p=0.009) was demonstrated. There was no significant improvement in anterior 
nasal discharge (p=0.129). Significant improvement was recorded in nasal endoscopic 
findings of oedema (p=0.001), erythema (p=0.001), purulent discharge (p=0.002) and nasal 
crusts (p=0.001). There was no significant improvement in nasal NO production. A 
significant improvement occurred in NAR (p=0.05) as measured by rhinomanometry. We 
conclude that 0.05% NaOCl is suitable for use in nasal epithelium as a lavage in humans. We 
have demonstrated that if applied twice daily for 3 months, 0.05% NaOCl lavage may be a 
good alternative to systemic antibiotics in the treatment of CRS with recurrent infection. 
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INTRODUCTION 
 
Chronic rhinosinusitis  
Chronic rhinosinusitis (CRS) is one of the most common health care problems with major 
economic implications. The etiology of this disease is multifactorial. The role and type of 
bacteria in the pathogenesis of CRS is still debatable. Yet the conventional medical therapy of 
CRS includes antibacterial treatment. Although the choice of antibiotics should be culture 
directed, in most cases, empiric selection of antibiotic is still preferred [1, 2]. A growing 
number of antibiotics are being gradually ineffective against the common isolates of CRS. 
The probable causes of the resistance of micro-organisms to antibiotics are considered to be 
multiple, including inappropriate use, spread of antimicrobial resistant bacteria across 
different countries due to increased travel, and increased use in agriculture, fisheries and 
animal husbandry. The introduction of new antibacterial drugs has declined and any new drug 
that has been introduced is challenged with rapidly developing resistance [2-5]. Thus novel 
and alternative therapy for bacteria in CRS is becoming significantly more important. 
CRS is usually treated with nasal irrigation or lavage, topical steroids, a long course of broad-
spectrum antibiotics and anti histamines as indicated [5, 6]. Sinus diseases resistant to 
traditional medical therapy are usually managed by endoscopic sinus surgery (ESS) [7]. ESS 
is a reasonably successful treatment [1]. Nevertheless a significant percentage of patients are 
not improved after ESS. A number of alternative treatment modality has been reported for 
management of resistant CRS, including home i.v. antibiotics for 6 weeks [8], selective sinus 
irrigation with topical antibiotics and steroids [9] and nebulized aerosol therapy [6]. 
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CRS can have a major financial impact in terms of both “direct” and “indirect” costs. With 
85% of CRS patients of working age (between 18-65 years old), indirect costs such as 
“abstenteeism” (missed work days) and “presenteeism” (decreased productivity at work) 
significantly add to the economic burden of the disease [1]. Direct costs include radiography, 
hospitalization and medication. The annual expenditure of the pharmacologic management of 
CRS before surgery and after surgery has been reported to be US$ 1,220 and US$ 629 per 
patient per year, respectively, in the United States [Figure 1] [10]. Surgical costs averaged 
US$ 6,490 per patient. Thus, where cost constraints are important careful considerations of 
alternatives are crucial.  
Figure 1: Annual expenditure of the pharmacologic management 
of chronic rhinosinusitis in the United States [10] 
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Sodium hypochlorite  
Sodium hypochlorite (NaOCl) is a well known bleaching and disinfecting agent that has been 
found to be effective against several organisms [11-19]. NaOCl has been found to be effective 
against Staphylococcus aureus (SA) [11-16] and other organisms including Pseudomonas 
aeruginosa [18], Candida albicans [18] and Vibrio vulnificus  along with other 18 vibrio 
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species [19]. In fact it has been found to be effective in killing virtually all of the micro-
organisms known to infect burn patients [14]. 
NaOCl was used as an irrigant in treating wounds by Bunyan, who during World War II, used 
it as a topical antiseptic in burn therapy by initially irrigating with 0.2% NaOCl and then 
covering with silk occlusive envelopes containing 0.05% NaOCl. However the antiseptic 
property had been observed by Koch as early as 1880s and Dakin had used various NaOCl 
solutions for treating wounds during World War I [14, 18, 20]. Nowadays NaOCl is the most 
commonly used endodontic irrigant because of its physico-chemical and antibacterial 
properties [11, 17, 20-22]. 
The exact mechanism of microbial killing of NaOCl has never been determined. It dissociates 
in water to Na+ and OCl-/HOCl (hypochloric acid). The active chlorine is a strong oxidizing 
agent. Substantial evidence suggests that chlorine exerts its antibacterial effect by the 
irreversible oxidation of -SH groups of essential enzymes, disrupting the metabolic functions 
of the bacterial cell. Chlorine may also combine with cytoplasmic components to form N-
chloro compounds, toxic complexes that destroy the micro-organism. However, the first 
contact oxidation reactions of chlorine with bacteria may lead to the rapid killing of bacterial 
cells even prior to the formation of N-chloro compounds in the cytoplasm [14, 20, 22]. 
Selection of appropriate concentration of NaOCl is based on a balance between antimicrobial 
affectivity and tissue toxicity. The choice of concentration traditionally ranges from 0.5% to 
5.25% and sometimes as high as up to 10% [17]. Nevertheless bactericidal effect of NaOCl 
has been observed in concentration as low as 0.025% when used as a fluid dressing [23]. As 
an endodontic irrigant, the antimicrobial affectivity of 0.5% NaOCl was significantly less than 
5.25% NaOCl [22]. At 0.5% concentration, NaOCl efficiently decontaminated split thickness 
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cadaveric skin contaminated with methicillin resistant strains of SA. Even though 0.1% 
NaOCl could significantly decrease the amount of bacteria, organisms could still be isolated 
from the medium at 10 min [18]. 
Increasing the time of exposure to NaOCl decreases cell viability. If the irrigation time is 
increased, 0.5% NaOCl has nearly the same bactericidal effect as 5.25% NaOCl when being 
used as an endodontic irrigant [21]. It has also been demonstrated [14] that 0.5% NaOCl was 
inappropriate for long term maintenance. After 2 weeks of continuous treatment of burn 
wound with NaOCl gauze soaks, a marked toxicity was noticed in the epidermal cells of the 
treated areas. The basal cell isolates from treated areas were inhibited in their growth and 
tissue culture. Conversely 0.1% NaOCl was found to be of low toxicity for long term 
maintenance. 
Thus before applying NaOCl in vivo we first evaluated the response of reconstituted nasal 
epithelium from primary nasal epithelial cells cultured in vitro to different concentration of 
NaOCl and exposure time. 
F-actin network 
F-actin based cytoskeleton stabilizes cell shape and plays important roles in the distribution of 
membrane proteins, in the regulation of transmembrane transport pathways and possibly in 
sensing cell volume changes. F-actin is directly linked to many components of the tight 
junction (TJ) complex [24, 25]. Thus alteration in the expression of F-actin may have 
profound effect on TJ structure and barrier function of epithelial cells and inversely TJ 
modulation has effect n F-actin [26].  
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Ezrin 
Establishment of epithelial cell polarity is initially directed by cell adhesion molecules 
followed by organization of the cytoskeleton and sorting of proteins to basolateral and apical 
compartments. A central role in organizing and regulating specialized apical membrane 
proteins is played by polarized Ezrin, Radixin and Moesin (ERM) that is derived from a large 
dormant cytoplasmic pool. Dormant ERM proteins present in a folded conformation masking 
cortical-membrane and F-actin binding site. When polarized, ERM maintain an activated 
conformation linking cortical membrane proteins and cytoskeletal actin. Differentiation of the 
airway epithelium is highly regulated to generate ciliated and secretory goblet cells [27].  
Thus tracking the expression of ezrin can help to indicate the polarity and differentiation of 
ciliated nasal epithelial cells. 
Transepithelial electrical resistance  
Tight junctions, characteristically located at the apico lateral borders of epithelial cells, 
selectively regulate the passage of water, ions, neutral molecules, and inflammatory cells 
through the paracellular pathway (the fluid-filled spaces between cells). These junctions 
define the limits of distinct fluid compartments, vital to homeostasis, and contribute to the 
maintenance of cell polarity. The most effective way to assess the functioning of TJ’s is to 
measure the capacity of an intact epithelium to generate a transepithelial electrical resistance 
(TER). The TER generated across an epithelium is determined by the ion transport properties 
of its component cells and the selective and restrictive barrier afforded by the TJ [28]. 
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Clinical evaluation 
The European position paper on Rhinosinusitis and Nasal Polyps [1]  has defined CRS 
(including nasal polyps) as inflammation of the nose and the paranasal sinuses (PNS) 
characterized by two or more symptoms [Table 1] lasting at least for 12 weeks and either 
endoscopic signs and/or Computed tomographic changes. 
The strength of the subjective symptoms can be estimated using a visual analogue scale 
(VAS). The VAS is a self-reporting device that measures the magnitude of the state in a line 
that is horizontally placed with two poles anchored at both ends from 0 (none) to 10 (severe or 
maximum) [Figure 2]. Participants or the examiner place a mark somewhere along the line 
that best indicates the magnitude of the state according to the perception of the patient.  
VAS offers a reproducible and quantifiable evaluation of the patient’s rhinosinusitis-specific 
symptoms, which may be a better means of evaluating symptom intensity than simply asking 
whether the patient feels better, the same or worse [7]. 
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 Figure 2 : Visual analogue scale recording for subjective
sensation of nasal obstruction  20
Nitric oxide  
Nitric oxide (NO) found in the upper and lower respiratory tract is a sensitive indicator of the 
presence of inflammation and ciliary dysfunction and can be used as an outcome measure 
after therapy [1]. The NO levels produced in the upper airway are among the highest 
measured in the human body [29]. The chemiluminescence technique for detecting NO in the 
exhaled nasal breath is currently the most widely accepted method of measurement [30]. 
Rhinomanometry  
Rhinomanometry (Rhm) has been applied successfully for a long time and have gained wide 
acceptance in the objective assessment of nasal patency by measuring nasal airway resistance 
(NAR). NAR is measured by assessing nasal flow at a constant pressure. Rhm can assist in 
making the correct diagnosis, monitor treatment effects and outcome measurements, evaluate 
new therapeutic strategies and avoid inappropriate surgery [31]. 
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Table 1: Clinical definition of Chronic Rhinosinusitis/nasal polyps [1] 
Chronic Rhinosinusitis (including nasal polyps) is defined as: 
 
• Inflammation of the nose and the paranasal sinuses characterized by two 
or more symptoms for more than 3 months: 
 
- Blockage/congestion; 
- Discharge: anterior/post nasal drip; 
- Facial pain/pressure; 
- Reduction or loss of smell; 
 
and either 
 
• Endoscopic signs: 
 
- polyps; 
- mucopurulent discharge from middle meatus; 
- oedema/mucosal obstruction primarily in middle meatus, 
 
and/or 
 
• CT changes: 
 
- Mucosal changes within ostiomeatal complex and/or sinuses. 
 
 
 22
AIM OF THESIS 
 
The main objective of this study was to evaluate whether NaOCl might be an efficient and 
cheap method of nasal lavage as an alternate to systemic antibiotics in ameliorating clinical 
symptoms of chronic rhinosinusitis without significantly diminishing epidermal cell 
viabilities and causing much discomfort to the patient. 
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MATERIAL AND METHOD 
 
SODIUM HYPOCHLORITE 
Preparation of NaOCl solution 
As a source of NaOCl solution, Amuchina Med (ACRAF SpA, Genova-Italia) [Figure 3] 
containing 0.5% NaOCl was used. This product is available in all pharmacies.  
 
 
The 0.55% NaOCl was
concentration of 0.05%
(0.05 X 
The 0.05% NaOCl wa
(A)]. Each bottle can h
(0.05 X 
 Figure 3 : Commercially available
Amuchina ® bottles  diluted with normal saline (0.9% Sodium chloride) to get the desired 
 NaOCl using the following formula, 
100)/ 0.55 = 9.1ml of 0.5% Amuchina in each 100 ml of solution 
s put into a Sinus Rinse bottle (NeilMed Products, USA) [Figure 4 
old up to 240 ml of the solution. For 240 ml of 0.05% NaOCl Solution: 
240)/0.55 = 21.8ml of 0.55% Amuchina in each 240 ml of solution 
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Each patient was demonstrated how to prepare the solution and the method of administration 
at home. They were given a 20ml syringe to fill up with Amuchina Med (0.55% NaOCl) and 
add to the sinus rinse bottle. The bottle was then filled up with normal saline (0.9% Sodium 
Chloride) up to the 240 mark. After gently shaking the bottle they were advised to apply the 
rinse. 
Application 
The patients were advised to rinse each of their nasal cavities two to three times, twice daily 
for three months with the prepared 0.05% NaOCl solution. They will prepare the solution 
every morning before application and use it twice daily (morning and afternoon) [Figure 4 
(B)]. They  were advised to discard the remaining solution at the end of the day. 
 
Figure 4 (A) : Sinus Rinse bottle 
(NeilMed Products, USA) 
 
Figure 4 (B): Application of solution 
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IN VITRO 
Cilia and Epithelial cell viability 
The three factors that may influence the toxicity of any individual agent within a in vitro 
primary cell culture assay are (1) cell number, (2) duration of exposure and (3) nature of the 
antiseptic diluents [32]. Different dilutions of NaOCl (0.5% and 0.05%) with change in 
duration of exposure (5min and 15min) were tested in vitro on nasal mucosal cells. All of the 
treatment was done twice daily for five consecutive days. The viability and regeneration of 
the treated cells and cilia were recorded.  
Airway epithelia 
Biopsies of nasal mucosa were obtained from non-involved male and female patients 
according to the guidelines of the Ethical Committee for Clinical Studies of the Geneva 
University Hospital (Number 04-096). Informed consent was obtained from all subjects. 
Culture of primary epithelial cells from biopsies was according to the protocol described by 
Karp et al. [33].  In summary, epithelial cells are dispersed from the biopsies and plated at a 
density of 5 X 105  cells/cm2 onto 0.6 cm2 collagen-coated filters (Millipore, Molsheim, 
France). Cells are cultured in Dulbecco's modified Eagle's medium (DMEM) -nutrient 
mixture F-12 (F-12) (invitrogen, Basel, Switzerland), supplemented with 2% Ultroser G 
(Biosepra, Ciphergen Biosystems, Cergy-Saint-Christophe, France), 100 U/ml penicillin and 
100 mg/ml streptomycin. After one day, filters are taken at the air-liquid interface for the next 
2-3 weeks.  
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Measurement of the epithelial barrier 
Transepithelial resistance (TER) of the reconstituted epithelia was assessed using a Millicel 
ERS Volt-ohm meter (World Precision Instruments, New Haven, CT).  
Experimental treatments 
The apical surface of reconstituted epithelia, featuring equivalent TER were exposed for 5 and 
15 min to one of the following conditions twice daily for five consecutive days: 1) untreated, 
2) NaOCl solution at a concentration of 0.05% and 0.5%. The experiments were stopped by 
washing of the epithelia in DMEM-F12 and metabolically active cells were evaluated using a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (thiazolyl blue) assay 
(Sigma). 
Immunostaining 
The reconstituted epithelia were fixed in 4% paraformaldehyde, permeabilized in 0.1% 
saponin and incubated for 1 hour to overnight with the rabbit polyclonal ezrin antibodies from 
Upstake (New York), diluted in (1:800) phosphate-buffer saline-1% BSA. After washing, the 
tissues were incubated again for 30 min with an appropriate secondary antibody in presence 
of Texas-red phalloidin from Molecular Probes (Leiden, The Netherlands), in order to label 
the F-actin network and delineate the cells. Filters were cut off from the culture inserts, 
mounted in Vectorshield-DAPI (VECTOR) between glass cover slips, and observed with an 
LSM 510 confocal microscope (Zeiss). 
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IN VIVO 
Patient selection criteria 
Adult patients with a history of CRS resistant to classical treatment including saline lavages, 
topical corticosteroids and short antibiotics were eligible for participating in the study. CRS 
has been defined according to The European position paper on Rhinosinusitis and Nasal 
Polyps [Table 1] [1]. They were recruited from the outpatient clinic of the Rhinology-
Olfactology unit of the Service of Otorhinolaryngology of the University Hospital of Geneva.  
Patients were excluded from the study in case of the presence of any disease or conditions 
associated with a higher risk of developing infection, except nasal anatomical abnormalities 
and rhinosinusitis.  
In addition to 0.05% NaOCl nasal lavages, each patient were given topically administered 
nasal steroid, to be applied twice daily along with NaOCl. They were followed up every 
month for three months starting from the baseline visit. At the end of three months the study 
was concluded. 
This experimental protocol (05-035) was accepted by the institution ethical committee and 
patients gave their informed consent. 
Symptom evaluation 
Patients recorded nasal (nasal obstruction, anterior and posterior nasal discharge, olfactory 
function and headache) symptoms on a VAS during the baseline visit and after three months 
of therapy.  
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Endoscopic examination 
Nasal endoscopy was carried out with a rigid endoscope 2·7 mm O0(Karl Stortz, Essen, 
Germany) by the same physician. The endoscopic images of the nose were evaluated by VAS 
twice, at the baseline visit and after three months of therapy. Nasal mucosal oedema, 
erythema, purulent discharge, crust and nasal polyps were evaluated. Nasal polyps can be 
classified in three clinical stages [34]; Stage 1: Polyps confined to the middle meatus, Stage 
II: Polyps extending beyond middle meatus and Stage III: Polyps totally occluding the entire 
nasal cavity. 
Nitric oxide measurements 
The level of NO was measured by chemiluminescence’s analyzer (Ecomedics, Drunten, 
Switzerland). The analyzer was calibrated daily and ambient NO was recorded before each 
maneuver. The subjects sat with a Teflon tube inserted inside the nostril ensuring a tight seal 
and then asked to take in a deep breath and maintain a full inspiratory position (valsalva 
maneuver). During the measurement subjects were relaxed with their mouths closed without 
straining.   
NO value to be recorded  
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Figure 5: Nasal Nitric Oxide measurement, ppb: parts per billion  
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 The breath was held for a minimum of 30s. Closure of the soft palate allowed analysis of the 
local NO concentration with free flow of ambient air or NO from one nostril to the other and 
subsequent direction into the analyzer. The value of the last plateau part of the trace of nasal 
NO was recorded [Figure 5]. Three measurements were taken and the mean recorded as the 
level of NO in the nose. The method of NO measurement is based on the 1997 European 
Respiratory Society Guidelines [35, 36]. NO measurements were taken twice, during baseline 
visit and after three months. 
Rhinomanometry measurements 
NAR (Pa/cm3/s) was measured by active anterior Rhm (Rhinometer 200; ATMOS, Germany) 
at the baseline and after three months. Intranasal pressure and flow signals were measured 
simultaneously, digitized and analyzed to calculate airflow in cm3 per second for each nostril 
after 10 normal breathings. Total NAR (tNAR) was then calculated with the following 
formula [37]: 
tNAR= (right NAR x left NAR ) / (right NAR + left NAR) 
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STATISTICAL ANALYSIS 
 
All statistical analysis was performed using SPSS (SPSS Inc. Chicago, Illinois) statistical 
package (version 10.0) for windows. Data are given as Mean ± Standard error of mean 
(SEM). 
Student t-test was performed to compare the changes of TER of reconstituted nasal epithelial 
calls. A value of p<0.05 was considered to be statistically significant. 
A Wilcoxon signed rank test of paired differences was performed for all pair-wise 
combinations of VAS scores for subjective symptom and nasal endoscopic findings. The 
mean paired difference (pre treatment minus post treatment) and p value of the Wilcoxon 
signed rank test were reported. P< 0.05 was considered to be statistically significant. 
For comparison of pre- and post- treatment NO and NAR measurements, Wilcoxon signed 
rank test was used. P<0.05 was considered to be statistically significant. 
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RESULTS 
 
Fourteen patients (6 females and 8 males; mean age 41 years, age range 18 - 59 years) 
completed the study. Except for one, all patients were Caucasians. Eight of the patients were 
admitted to the hospital during the last three years, all of who underwent surgical procedures 
of the nose. Three of the patients were employed in the health sector and performed 
administrative work. None of the patients had any factors that might be associated with 
increased risk for developing persistent infection. All the patients had monthly follow ups for 
three months after the initiation of treatment. 
IN VITRO 
F-actin network 
F-actin network labeling forms a distinctive ring at the periphery of cells. The gradual 
depletion of this ring (red) in cells is comparatively more obvious when treated twice daily for 
four consecutive days for 15 minutes [Figure 6] than those for 5 minutes [Figure 7]. 
Depletion in cells treated for 5 minutes is less but more comparable with the cells at the 
beginning of treatment [Figure 8]. A significant loss of F-actin network and loss of cells is 
noticeable in cells exposed to the more concentrated NaOCl (0.5% NaOCl) after only 5 
minutes.  
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 Day 1 Day 2 
 Day 3 Day 4 
 
Figure 6: Confocal microscopic images of reconstituted nasal epithelial cells showing 
expression of ezrin (green) and F-actin network (red) delineating the cell outline after 
treatment with 0.05% Sodium Hypochlorite solution (prepared with PBS) exposed for 15 
minutes, twice daily for four consecutive days 
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Day 1 Day 2 
 Day 3 
Day 4 
 
Figure 7: Confocal microscopic images of reconstituted nasal epithelial cells showing 
expression of ezrin (green) and F-actin network (red) delineating the cell outline after 
treatment with 0.05% Sodium Hypochlorite solution (prepared with PBS) exposed for 5 
minutes, twice daily for four consecutive days. 
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Figure 8: Confocal microscopic images showing expression of ezrin (green) and F-actin 
network (red) delineating the cell outline in reconstituted nasal epithelial cells at the 
beginning of treatment. 
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Expression of ezrin in the apical domain of reconstituted epithelia. 
After exposure to undiluted (0.5% NaOCl) and one tenth dilution (0.05% NaOCl) of 
Amuchina for 5 minutes, the epithelia cells were observed under confocal microscope for 
ezrin expression. No ezrin was detected in the epithelia exposed to 0.5% NaOCl [Figure 9a] 
even as early as 5 minutes. On the other hand expression of ezrin was observed in the cells 
exposed to diluted Amuchina (0.05% NaOCl) [Figure 9b]. 
In Figure 10b, Z stack images of confocal microscopy demonstrate polarized apical 
expression of ezrin in epithelia cells after 4 days of treatment, twice daily for 5 minutes with 
0.05% NaOCl which is comparable to the control [Figure 10a]. However, in case of epithelia 
cells treated for 15 minutes [Figure 10c], the thick apical band expression of ezrin is absent. 
There is redistribution of Ezrin indicating loss of polarity of cells. Absence of apical ezrin 
may be due to loss of ciliated cells.  
Figure 6 and Figure 7 compare expression of ezrin in cells treated with 0.05% NaOCl, two 
times daily for four consecutive days, 15 minutes and 5 minutes respectively. Ezrin 
expression reduction was relatively more pronounced in the epithelia cells treated for 15 
minutes. It is mentionable that no ezrin was expressed at all in cells exposed to 0.5% NaOCl 
for 5 minutes one time only [Figure 9a].  
Changes in transepithelial resistance  
TER values of cells treated with 0.05% NaOCl exposed for 5 minutes and 15 minutes 
respectively were compared. In Figure 11 the changes of TER values with time are 
expressed. 
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a) 0.5% Sodium hypochlorite 
 
b) 0.05% Sodium hypochlorite 
 
Figure 9: Confocal microscopic images of reconstituted nasal epithelial cells showing 
expression of ezrin (green) and F-actin network (red) delineating the cell outline after 
exposure to 0.5% and 0.05% Sodium Hypochlorite solution (prepared with PBS). 
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 a) Control 
 b) 5 minute 
 
c) 15 minutes 
 
Figure 10: Confocal microscopic Z stack images of reconstituted nasal epithelial cells 
showing expression of ezrin (green) and F-actin network (red) delineating the cell outline at 
the end of treatment for 4 days of a) control (PBS) and after exposure for twice daily to 0.05% 
Sodium Hypochlorite solution for b) 5 minutes and c)15 minutes. 
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Figure 11: Transepithelial resistance changes of reconstituted epithelia at the end of treatment 
for 4 days of a) control (PBS) and after exposure for twice daily (“M” morning and “A” 
afternoon) for five days to 0.05% Sodium Hypochlorite solution for b) 5 minutes and c) 15 
minutes. Mean ± SEM 
 
Values are given as Mean ± SEM. TER was measured twice daily for five days. A Student t 
test was performed to compare the changes in TER of control cells and cells treated for 5 
minutes and 15 minutes with 0.05% NaOCl with TER value of cells at day Zero at the 
beginning of treatment. There was a statistically significant (p<0.001) drop in TER of control 
cells and treated cells (5 and 15 minutes) at the end of day 5 in comparison to TER of cells at 
day Zero. Sodium hypochlorite was diluted with (phosphate buffered saline) PBS. To validate 
whether the drop in TER was due to NaOCl or PBS treatments, we performed the experiment 
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in DMEM-F12 containing 25mM of N-2-hydroxyethylpiperazine-N -2-ethanesulfonic acid 
(HEPES) pH 7.4 that will stabilize the pH at the apical surface of the epithelia, during 
treatment [Figure 12]. At the end of 5 days the TER value in control cells treated with 
DMEM-F12 was 1131 ± 458 Ω/cm2, a 57% decrease from the TER values at the beginning of 
the experiment. The TER values of cells treated with PBS (255 ± 36 Ω/cm2) had a 90% 
decrease from initial TER values. 
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Figure 12: Comparison of transepithelial resistance of reconstituted nasal epithelial cells at 
the end of treatment for two times per day (“M” morning and “A” afternoon) for five days 
with 0.05% NaOCl (control, 5 and 15 minutes), and with PBS and DMEM-F12 separately. 
Mean ± SEM 
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MTT assay 
Treatment with NaOCl induced a reduction in TER, which, however, was not paralleled by a 
decrease in the viability of epithelial cells, as evaluated by the MTT assay.  This drop 
increased permeability and presumably is correlated to the disorganization of TJ belts that 
surround epithelial cells. Opening of the paracellular route induces a loss of polarity with 
redistribution of apical marker to basolateral domains. These preliminary data suggest that 
disruption of the tight junction might lead to a disorganization of F-actin as well as the 
redistribution of ZO-1 and other TJ's associated molecules. However, further experiments will 
be required in order to validate the possible changes in the  F-actin cytoskeleton as well as  
the localization of TJ proteins (occludin and claudins) and ZO-1 during the 5 day treatment.  
IN VIVO 
Nasal Subjective Symptom Score and Nasal endoscopic findings 
The degree of variability of the pre and post treatment data is depicted as a box-and-whiskers 
plot in Figure 13 and Figure 14. A thick vertical line indicates the median value, a horizontal 
shaded box represents the interquartile range between the 25th and 75th percentile of the data. 
Mean of the VAS values (pre and post treatment) is given in Table 2. Table 3 illustrates the 
mean and confidence interval of the individual difference of VAS at the end of 3 months of 
treatment with NaOCl. Statistically significant improvement was found in all nasal 
endoscopic findings (p<0.05). In case of subjective symptoms, statistically significant 
improvement was found for all symptoms, except only for anterior (Wilcoxon sign rank test, 
p=0.106) nasal discharge. 
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C: Posterior Nasal Discharge
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Figure 13. Comparison of subjective symptoms recorded by visual analogue scale, pre and 
post treatment. The Box-and-whiskers plot represents the median and the 25th and 75th 
percentile. (*p<0.05, **p<0.01, ***p<0.001 and NS: Not significant ) 
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C: Purulent Nasal Discharge
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Figure 14. Comparison of nasal endoscopic findings recorded by visual analogue scale, pre 
and post treatment. The Box-and-whiskers plot represents the median and the 25th and 75th 
percentile. (*p<0.05; **p<0.01 and ***p<0.001) 
 
 
 
 
 43
Table 2 : Mean of the visual analogue scale values of subjective symptoms and nasal 
endoscopic findings (n=14). 
 
 
     Mean (±SE)  Minimum Maximum 
 
 
Subjective Symptom Score 
Nasal Obstruction 
Pre-treatment   5.78 (±0.72)  2  10 
Post-treatment   2.00 (±0.57)  0  7 
Anterior Nasal Discharge 
 Pre-treatment   3.92 (±0.99)  0  10 
 Post-treatment   2.43 (±0.61)  0  6 
Posterior Nasal Discharge 
 Pre-treatment   4.75 (±0.79)  0  10 
 Post-treatment   2.00 (±0.56)  0  6 
Smell disturbance 
 Pre-treatment   5.39 (±1.07)  0  10 
 Post-treatment   1.54 (±0.92)  0  10 
Headache 
 Pre-treatment   4.29 (±1.14)  0  10 
 Post-treatment   0.93 (±0.46)  0  5 
Nasal Endoscopic Findings 
Oedema 
 Pre-treatment   6.00 (±0.74)  0  9.5 
Post-treatment   1.29 (±0.41)  0  5 
Erythema 
 Pre-treatment   6.93 (±0.71)  0  10 
Post-treatment   1.04 (±0.30)  0  3 
Purulent discharge 
 Pre-treatment   7.75 (±0.94)  0  10 
Post-treatment   1.00 (±0.55)  0  7 
Crusts 
 Pre-treatment   7.64 (±0.83)  0  10 
Post-treatment   0.89 (±0.44)  0  6 
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Table 3: Mean ± Standard error of mean (SEM) difference in the improvement of visual 
analogue scale scores of subjective symptoms and nasal endoscopic findings after treatment 
 
 
Mean of   95% Confidence P value* 
change (±SEM) Interval 
         
 
Subjective symptom score 
Nasal Obstruction   3.79 (±0.61)  2.48  to 5.09  P = .001 
Nasal Discharge 
Anterior   1.50 (±1.03)  -0.72 to 3.72   P = .129 
 Posterior   2.75 (±0.96)  0.68 to 4.82  P = .018 
Smell disturbance   3.86 (±0.96)  1.80  to 5.92  P = .007 
Headache    3.36 (±0.94)  1.32  to 5.39  P = .009 
 
Nasal Endoscopic Findings 
Oedema    4.71 (±0.70)  3.20  to 6.23  P = .001 
Erythema    5.89 (±0.91)  3.93  to 7.85  P = .001 
Purulent discharge   6.75 (±0.96)  4.69  to 8.81  P = .002 
Crusts     6.75 (±0.81)  5.01  to 8.49  P = .001 
 
 
* Wilcoxon sign rank test 
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Four of our patients had nasal polyps. All of them showed mild improvement in the nasal 
polyp stage [34]. Two patients had Stage 1 nasal polyposis, which after treatment showed 
remission to Stage 0. The other two had Stage 2 and 3 which three months after treatment 
became Stage 1 and 2 respectively [Table 4]. 
 
Table 4: Changes in nasal polyp stage [34] and smell disturbances after treatment with 
Sodium Hypochlorite (n=4) 
  Pre treatment      Post treatment 
Polyp  Smell  Nasal   Polyp   Smell  Nasal 
Stage  disturbance obstruction  stage  score  obstruction 
 
1  6  4   0  0  0 
1  0  9   0  0  7 
2  5  5   1  0  4 
3  10  8   2  10  1 
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Nitric Oxide measurement 
Pre- and post- treatment NO was measured in 10 patients only due to unavailability of 
equipment. The pre- and post- treatment NO, Mean ± SEM was 366.75 ± 97.94 ppb and 282 ± 
73.26 respectively. The difference was not statistically significant. (p=0.06; Wilcoxon signed 
rank test). Figure 15 illustrates in error bars the Mean ± 95% CI of pre- and post- treatment 
NO values. 
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Figure 15: Mean ± 95% Confidence Interval of pre- and post- treatment values of Nitric 
Oxide. 
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Nasal Airway Resistance  measurements 
Mean tNAR decreased from 0.45 Pa/cm3/s before therapy to 0.35 Pa/cm3/s after three months 
of 0.05% of NaOCl, corresponding to a 33% decrease. There was a statistically significant 
decrease in NAR (p=0.05; wilcoxon signed rank test). Figure 16 illustrates the Mean ± 95% 
CI of pre- and post- treatment tNAR values. 
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Figure 16: Total Mean ± 95% Confidence Interval of pre- and post- treatment values of nasal 
airway resistance 
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Discussion 
 
The main finding of this study is that NaOCl nasal lavages seem to be a safe, cheap and 
efficient alternative to systemic antibiotics in the medical treatment of CRS. Previous studies 
have demonstrated the efficacy of treating infection with NaOCl. However no study was 
found in the literature on the use of NaOCl in treating CRS.  Additionally the cellular effects 
of NaOCl may not necessarily be comparable in all tissues [38].  Hence there was a need to do 
in vitro test for an appropriate concentration of NaOCl, duration of exposure with nasal 
epithelium that would not be harmful yet bacteriocidal, before in vivo application. 
The depletion of F-actin network in our study indicated that cytotoxic effect of NaOCl 
depends on both concentration and duration of exposure. Chang et al [38] demonstrated a 
dose-dependent inhibition of mitochondrial activity by NaOCl and suggested that the 
cytotoxic effect might be via DNA or RNA synthesis. However the cellular effects of NaOCl 
may not necessarily be comparable in all tissue. 
Expression of Ezrin agreed with alteration in F-actin network. Five minutes after exposure to 
0.5% NaOCl, reconstituted epithelia had a reduced number of ciliated cells and the altered 
ciliated cells failed to express ezrin. Ezrin expression in cells exposed to 0.05% NaOCl was 
also far more reduced compared to cells exposed for 5 minutes. Ezrin expressed in the apical 
membrane of epithelial cells lining the airways is an indicator of polarity and cell 
differentiation. Thus the in vitro response by F-actin network and ezrin expression of 
reconstituted nasal epithelium have demonstrated that 0.05% NaOCl induced less epithelial 
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cell cytotoxicity than 0.5% NaOCl. We also demonstrated that 5 minutes exposure twice daily 
for consecutive days to 0.05% NaOCl was less harmful than 15 minutes exposure.   
The alteration of F-actin network and ezrin expression are frequently associated with changes 
in the appearance and function of TJ’s. We therefore examined the effect on TER. There was 
a statistically significant drop (p<0.001) in TER at the end of 5 days in control cells and cells 
treated with 0.05% NaOCl for 5 minutes and 15 minutes daily in comparison to TER values at 
day zero. The reduction of TER in cells not treated with NaOCl might indicate that the 
changes have been due to the diluent (PBS) rather than NaOCl. But when dilutions were made 
in DMEM-F12, the reduction in TER was not so drastic in control cells, at the end of five day 
treatment. The discrepancy between ezrin expression at the cell surface and F-actin network 
may be due to a change in the cell polarity, possibly due to the opening of TJ of the 
reconstituted nasal epithelia. We thus propose to investigate whether, upon treatment, TJ are 
modulated and if the paracellular route is then made accessible to bacteria or inert particles. 
Furthermore, it will be interesting to investigate whether bacteria infected nasal reconstituted 
epithelial cells are still responsive to NaOCl  and then, to evaluate the response in term of 
TER and bacterial killing.    
Application of NaOCl in soaked gauze or dressing would have increased the exposure time 
and thus increase the bactericidal effect [21].  However this may raise the toxicity of NaOCl 
causing noticeable epithelial cell damage [14]. In addition a soaked gauze or a dressing can 
cause obstruction in the nasal airway resulting in difficulty of respiration.  
We have demonstrated that increasing the time of exposure to 0.05% NaOCl may decrease 
cell viability. Thus when applied for consecutive days, it is more suitable if the contact period 
 50
is not prolonged. Such application can be made by lavage or irrigation where the solution 
washes the surface area.  
Thus to see the clinical efficacy of NaOCl, we administered 0.05% NaOCl twice daily 
continuously for three months on both nostrils with Sinus Rinse bottle (NeilMed Products, 
USA). These bottles were easy to use and provided a smooth flow of lavage in the nasal 
cavity. A lavage has certain advantages over the administration of topical or i.v. antibiotics. 
Any watery solution removes secretions and crusts from the nose and irrigating the nasal 
cavity in itself would therefore produce therapeutic effect [5]. The action of the lavage may be 
effected through mechanical cleansing of the sinus surface, altering the composition of the 
mucus or reducing local concentrations of bacterial or fungal organisms, their toxins or pro-
inflammatory substances released during inflammatory responses to these [6].  
The two main sources of NaOCl are pharmaceutical supplies or commercially available 
household bleaches. NaOCl from commercial sources have been used for many years for 
clinical purpose without significant problems [17]. Thus the solutions may be available at a 
very affordable price. Often the price of syringes and needles are greater than the NaOCl it 
contains [14, 41]. 
In our study as an alternative therapy for persistent CRS we have demonstrated significant 
improvements in symptoms with the administration of 0.05% NaOCl. Except for anterior 
nasal discharge (AND), a statistically significant improvement was recorded for nasal 
obstruction, posterior nasal discharge, smell and headache. Nasal endoscopic findings 
demonstrated significant reduction in oedema, erythema, purulent discharge and nasal crusts.  
After 0.05 % NaOCl therapy, we recorded significant improvement in CRS-specific symptom 
and endoscopic findings score except for AND symptom score. The failure of significant 
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improvement in AND may be explained by increased flow due to decreased crust and 
widening. Our post treatment CRS symptom scores were similar to sinus symptom scores 
recorded in 100 normal individuals by Walker and White [42] indicating the efficacy of 
treatment [Table 5].   
Objective Rhm recordings have shown that NAR was significantly reduced at the end of 3 
months of treatment. Active anterior Rhm is a reliable method of assessing the functional 
status of the nasal cavities in different situations [43].   
NO levels did not show statistically significant changes between pre- and post- treatment 
values even though symptomatic and endoscopic findings documented improvements. In fact 
in our study the post treatment NO level was higher. This lack of improvement in NO level 
correlates with a study carried out by Cervin et al. [44], who demonstrated no significant 
improvement in NO level despite of significant improvement in symptoms in patients who 
received long term low dose erythromycin therapy for CRS after 3 months. After 12 months 
of therapy there was a trend toward an increase in nasal NO. This can be explained as a result 
of the gradual restoration of normal epithelium function due to appearance of ciliated cells, 
reduction of inflammation and reduction in nasal secretion. It will be interesting to follow up 
our patients for a longer period to monitor if there is an increase or decrease in NO levels. 
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Table 5.  Mean (minimum and maximum) scores from normal subjects [42] and patients three 
months after treatment with 0.05% Sodium Hypochlorite. 
 
 
Symptoms    Normal subjects [56]  Patients   
post-treatment 
 
     (n=100)   (n=14) 
 
Nasal obstruction   2.3 (0 to 7)   2.0 (0 to 7) 
Nasal Discharge   2.0 (0 to 7)   2.2* (0 to 6) 
Disturbance of smell   1.7 (0 to10)   1.5 (0 to 10) 
Headache    1.2 (0 to 8)   0.9 (0 to 5)  
*Average of anterior and posterior nasal discharge score 
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CONCLUSION 
 
Our in vitro test demonstrated that 0.05% NaOCl may be used on nasal epithelium and found 
it to be effective in treating persistent CRS as an alternative to antibiotic therapy. With no 
known side effects and risk of developing tolerance as well as due to its cheap cost and 
method off application, nasal lavage with NaOCl is advantageous over other alternative 
therapies and should be recommended for the treatment of CRS.  
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